Evidence map›Paper›PMID 31007852›Full record

ArticleOncotarget2019

Correction: HOTAIR regulates HK2 expression by binding endogenous miR-125 and miR-143 in oesophageal squamous cell carcinoma progression.

Jian Ma, Yanxin Fan, Tingting Feng, Fangjun Chen, Zhipeng Xu, Suqing Li, Qingfeng Lin, Xiaoting He, Weihong Shi, Yang Liu and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. S100A10 promotes glycolysis and malignant progression of CCA by activating the HK2/ERK signaling pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Review
  3. Article
  4. Progress of HOTAIR-microRNA in hepatocellular carcinoma.Hereditary cancer in clinical practice · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Jian MaDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Yanxin FanJiangsu Cancer Hospital, Medical School of Nanjing University, Nanjing 210008, Jiangsu Province, China.
Tingting FengDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Fangjun ChenThe Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing 210008, Jiangsu Province, China.
Zhipeng XuDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Suqing LiDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Qingfeng LinDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Xiaoting HeDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Weihong ShiDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Yang LiuDepartment of Pharmacy, No.401 Hospital of Chinese People's Liberation Army, Qingdao 266071, Shandong Province, China.
Zhihua LiuState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.
Bin ZhuDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Xiufeng CaoDepartment of Surgical Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.21195.].

Identifiers

PMID31007852
PMCPMC6459342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.